124 related articles for article (PubMed ID: 35256754)
21. Prognostic Significance of CHEK2 Mutation in Progression of Breast Cancer.
Ansari N; Shahrabi S; Khosravi A; Shirzad R; Rezaeean H
Lab Med; 2019 Jul; 50(3):e36-e41. PubMed ID: 31220302
[TBL] [Abstract][Full Text] [Related]
22. A Comparison between CHEK2*1100delC/I157T Mutation Carrier and Noncarrier Breast Cancer Patients: A Clinicopathological Analysis.
Huszno J; Budryk M; Kołosza Z; Tęcza K; Pamuła Piłat J; Nowara E; Grzybowska E
Oncology; 2016; 90(4):193-8. PubMed ID: 26991782
[TBL] [Abstract][Full Text] [Related]
23. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
24. [CHEK2-mutation in Dutch breast cancer families: expanding genetic testing for breast cancer].
Adank MA; Hes FJ; van Zelst-Stams WA; van den Tol MP; Seynaeve C; Oosterwijk JC
Ned Tijdschr Geneeskd; 2015; 159():A8910. PubMed ID: 26332814
[TBL] [Abstract][Full Text] [Related]
25. Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers.
Kriege M; Jager A; Hollestelle A; Berns EM; Blom J; Meijer-van Gelder ME; Sieuwerts AM; van den Ouweland A; Collée JM; Kroep JR; Martens JW; Hooning MJ; Seynaeve C
J Cancer Res Clin Oncol; 2015 Oct; 141(10):1879-87. PubMed ID: 25958056
[TBL] [Abstract][Full Text] [Related]
26. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland.
Cybulski C; Lubiński J; Wokołorczyk D; Kuźniak W; Kashyap A; Sopik V; Huzarski T; Gronwald J; Byrski T; Szwiec M; Jakubowska A; Górski B; Dębniak T; Narod SA; Akbari MR
Clin Genet; 2015 Oct; 88(4):366-70. PubMed ID: 25330149
[TBL] [Abstract][Full Text] [Related]
27. Missense mutations (p.H371Y, p.D438Y) in gene CHEK2 are associated with breast cancer risk in women of Balochistan origin.
Baloch AH; Daud S; Raheem N; Luqman M; Ahmad A; Rehman A; Shuja J; Rasheed S; Ali A; Kakar N; Naseeb HK; Mengal MA; Awan MA; Wasim M; Baloch DM; Ahmad J
Mol Biol Rep; 2014 Feb; 41(2):1103-7. PubMed ID: 24390236
[TBL] [Abstract][Full Text] [Related]
28. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
29. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
Schmidt MK; Tollenaar RA; de Kemp SR; Broeks A; Cornelisse CJ; Smit VT; Peterse JL; van Leeuwen FE; Van't Veer LJ
J Clin Oncol; 2007 Jan; 25(1):64-9. PubMed ID: 17132695
[TBL] [Abstract][Full Text] [Related]
30. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR
JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374
[TBL] [Abstract][Full Text] [Related]
31. A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk.
Wang N; Ding H; Liu C; Li X; Wei L; Yu J; Liu M; Ying M; Gao W; Jiang H; Wang Y
Oncogene; 2015 Oct; 34(40):5198-205. PubMed ID: 25619829
[TBL] [Abstract][Full Text] [Related]
32. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
33. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
[TBL] [Abstract][Full Text] [Related]
34. The risk of gastric cancer in carriers of CHEK2 mutations.
Teodorczyk U; Cybulski C; Wokołorczyk D; Jakubowska A; Starzyńska T; Lawniczak M; Domagała P; Ferenc K; Marlicz K; Banaszkiewicz Z; Wiśniowski R; Narod SA; Lubiński J
Fam Cancer; 2013 Sep; 12(3):473-8. PubMed ID: 23296741
[TBL] [Abstract][Full Text] [Related]
35. Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.
Kleiblova P; Stolarova L; Krizova K; Lhota F; Hojny J; Zemankova P; Havranek O; Vocka M; Cerna M; Lhotova K; Borecka M; Janatova M; Soukupova J; Sevcik J; Zimovjanova M; Kotlas J; Panczak A; Vesela K; Cervenkova J; Schneiderova M; Burocziova M; Burdova K; Stranecky V; Foretova L; Machackova E; Tavandzis S; Kmoch S; Macurek L; Kleibl Z
Int J Cancer; 2019 Oct; 145(7):1782-1797. PubMed ID: 31050813
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study.
Einarsdóttir K; Rosenberg LU; Humphreys K; Bonnard C; Palmgren J; Li Y; Li Y; Chia KS; Liu ET; Hall P; Liu J; Wedrén S
Breast Cancer Res; 2006; 8(6):R67. PubMed ID: 17132159
[TBL] [Abstract][Full Text] [Related]
37. Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.
Kotsopoulos J; Gronwald J; Karlan BY; Huzarski T; Tung N; Moller P; Armel S; Lynch HT; Senter L; Eisen A; Singer CF; Foulkes WD; Jacobson MR; Sun P; Lubinski J; Narod SA;
JAMA Oncol; 2018 Aug; 4(8):1059-1065. PubMed ID: 29710224
[TBL] [Abstract][Full Text] [Related]
38. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Metcalfe K; Lynch HT; Ghadirian P; Tung N; Olivotto I; Warner E; Olopade OI; Eisen A; Weber B; McLennan J; Sun P; Foulkes WD; Narod SA
J Clin Oncol; 2004 Jun; 22(12):2328-35. PubMed ID: 15197194
[TBL] [Abstract][Full Text] [Related]
39. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Rebbeck TR; Lynch HT; Neuhausen SL; Narod SA; Van't Veer L; Garber JE; Evans G; Isaacs C; Daly MB; Matloff E; Olopade OI; Weber BL;
N Engl J Med; 2002 May; 346(21):1616-22. PubMed ID: 12023993
[TBL] [Abstract][Full Text] [Related]
40. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.
Cybulski C; Wokołorczyk D; Jakubowska A; Huzarski T; Byrski T; Gronwald J; Masojć B; Deebniak T; Górski B; Blecharz P; Narod SA; Lubiński J
J Clin Oncol; 2011 Oct; 29(28):3747-52. PubMed ID: 21876083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
